Effect of Testosterone and Resistance Training on Cardiac Mass and Contractility in Men with COPD

Matthew J. Budoff1*, Songshou Mao1, Mehd Rambo1, Ronald J. Oudiz1 and Richard Casaburi2

1Division of Cardiology, The Department of Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA
2Rehabilitation Clinical Trials Center, The Department of Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA

Abstract

Introduction: Testosterone therapy and resistance training have been demonstrated to improve muscle mass and strength in patients with testosterone deficiency. However, the effects on cardiac mass and contractility of these interventions have not been identified in prospective placebo-controlled trials. The hypothesis of this trial was that resistance training and testosterone replacement would improve cardiac mass and contractility in men with COPD patients with low testosterone levels.

Methods: We conducted a 10-week trial in a 2 by 2 factorial design, randomizing 53 patients to replacement doses of testosterone enanthate (100 mg weekly) or placebo, as well as to a program of lower extremity resistance training or no exercise. We performed rest and exercise cardiac computed tomography (CCT) studies before and after 10 weeks of therapy to evaluate right and left heart function. Patients were injected with 40-50 ml of non-ionic, iodinated contrast and cine CCT images were obtained at rest. Patients were exercised to 60% of their maximal work rate on a semi-supine ergometer, then re-injected with another bolus of 40-50 ml of contrast and re-imaged. We evaluated cardiac output and left ventricular (LV) and right ventricular (RV) mass, LV and RV stroke volume, ejection fractions and end-diastolic volumes at rest and exercise, before and after therapy.

Results: 42 men with COPD (mean FEV1=40%pred, pre-bronchodilator) and low testosterone levels (mean=320ng/dl) completed the 10-week protocol. Factorial analysis demonstrated that testosterone, but not resistance training, increased LV and RV mass (by 4.9% and 8.3%, respectively). Resistance training, but not testosterone, was associated with increased LV ejection fraction at rest and during exercise (by 5.5% and 4.4%, respectively). In the entire study group, increases in both left and right ventricular mass were correlated with increases in lean body mass (assessed by DEXA) (r=0.49 and r=0.65, respectively).

Conclusions: In men with COPD, testosterone replacement and strength training are associated with distinct alterations in cardiac structure and function. Specifically, resistance training improved ejection fraction, while testosterone increased lean body mass and LV mass.

Keywords: Cardiac computed tomography; Exercise; Testosterone; Chronic obstructive pulmonary disease

Introduction

Dysfunction of the muscles of ambulation contributes to exercise intolerance in chronic obstructive pulmonary disease (COPD). Men with COPD have shown to have low testosterone levels which may further contribute to low muscle mass and muscle weakness. A few clinical studies of testosterone analogs in COPD have been published and have generally shown modest improvements in muscle mass, but have not shown unequivocal improvements in muscle strength [1-3]. Cellular studies have demonstrated androgen-mediated hypertrophic responses to testosterone replacement [4], and myocardial hypertrophy associated with testosterone replacement has been quite reproducible in animals [5], our study is perhaps the first study to evaluate this effect in humans. More convincing studies are available to show that programs of resistance training increase muscle mass and strength in COPD [6].

The hypothesis of the present study was that resistance training and testosterone replacement would increase cardiac mass and function while improving muscle mass and strength of the muscles of ambulation in a cohort of men with COPD whose circulating testosterone level was low. We hypothesized that resistance training and/or testosterone supplementation would result in significant improvements in cardiac mass and/or ejection fraction assessed by cardiac CT.

Methods

Patient population: subjects

The study population consisted of 52 men who were in a stable phase of their COPD, without recent exacerbations. Women were excluded because testosterone supplementation at the dose utilized would likely yield virulization. Entry criteria included: age 55-80 years, forced expiratory volume in one second (FEV1) ≤ 60% predicted [7] and an FEV1 to vital capacity (VC) ratio ≤ 60%. Subjects were ambulatory but not actively participating in an exercise program. Serum testosterone level was ≤ 400 ng/dl at screening; putting participants in the lower range of levels found in healthy elderly men. Patients unable to exercise, with a creatinine elevated to twice the upper normal limits or with known contrast allergies were excluded. All patients gave written informed consent under a protocol approved by the Institutional Review Board. Patients were enrolled in a study to evaluate the effects of testosterone replacement, as well as resistance exercise training, on pulmonary, cardiac and muscle function. Hormonal, body composition...
the week following the end of the intervention period. Patients underwent a rest and exercise CT study, followed by a 10-week and incremental cycle ergometer testing to determine maximal DEXA scan), leg muscle strength testing (by 1 repetition maximum) underwent pulmonary function testing, body composition testing (by testosterone or placebo. As part of the parent protocol [9], patients < or ≥ 67 years and FEV\textsubscript{1} < or ≥ 40% predicted. Investigators, study coordinators and subjects were blinded as to whether subjects received testosterone or placebo. As part of the parent protocol [9], patients underwent pulmonary function testing, body composition testing (by DEXA scan), leg muscle strength testing (by 1 repetition maximum) and incremental cycle ergometer testing to determine maximal exercise tolerance before and after the intervention. After screening, patients underwent a rest and exercise CT study, followed by a 10-week intervention period. The rest and exercise CT study was repeated within the week following the end of the intervention period.

Interventions

Resistance (Strength) training: The resistance training program focused on the muscles of ambulation. Sessions were held three times per week and were supervised by an experienced exercise trainer. Sessions were preceded by 5-10 minutes of warm-up and stretching exercises. Patients who were hypoxic during exercise received supplemental oxygen by nasal cannula. Resistance training consisted of seated leg press, seated leg curl, seated leg extension, standing calf raise and seated ankle dorsiflexion exercises, providing overload of lower extremity major muscle groups. In each training session, subjects performed 3 sets of each of the 5 exercises. For the first 4 weeks, the training target was 3 sets of 12 repetitions at 60% of the pre-training one-repetition 45 maximum. Training intensity was increased when subjects were able to complete all 36 repetitions for a given exercise. When 3 sets of 12 repetitions were achieved, loads were again increased. After 4 weeks of training, one repetition maximum values were reassessed and used for the remaining 6 weeks. Subjects performed 4 sets of 8-10 repetitions, using 80% of the new one repetition maximum for each of the 5 training exercises; intensity was subsequently advanced as tolerated. All participants were asked to abstain from any additional resistance training or anything more than mild endurance exercise outside of the protocol.

Testosterone supplementation: Subjects received 100mg of testosterone enanthate in sesame oil (Delaestryl, 200mg/ml, BioTechnology General, East Brunswick, NJ) or placebo (sesame oil) by intramuscular injection weekly for 10 weeks.

Electron beam tomography studies

The CT studies were performed with an Imatron C-150XLP Ultrafast scanner (GE-Imatron, San Francisco, CA.). Patients underwent resting CT to assess left ventricular (LV) mass and right ventricular (RV) mass, as well as resting cardiac output and RV and LV ejection fractions and end-diastolic volumes. Tomographic images without contrast were obtained to identify the appropriate scan level. A continuous electrocardiogram monitor was attached to the patient to facilitate triggering of the CT. An 18 gauge intravenous catheter was placed in an antecubital vein. Patients were positioned supine on the scanner’s couch then the couch was tilted axially 13 degrees with the feet down and slewed 13 degrees horizontally to the patient’s right to facilitate left ventricular short axis views. The circulation time was obtained using a bolus injection of 10cc of non-ionic iodinated contrast medium, as previously described by Feiring [13]. Rest CT images were obtained by scanning sequential levels for one cardiac cycle at a rate of 17 scans per second using electrocardiographic triggering during an injection of 30-40 cc of non-ionic contrast material. Up to 20 images per cardiac cycle were obtained for each level of the ventricle. Twelve
levels, each with 8 millimeter slice thickness, were obtained during each contrast injection at a rate of 8-10 ml/second.

**Exercise electron beam computed tomography:** After the rest CT, patients underwent submaximal exercise using a stationary supine bicycle ergometer to assess for exercise-induced changes in cardiac output, LV and RV ejection fractions. The exercise protocol has been described previously [13,14]. Work rate was increased by 25 Watts every 2 minutes to 60% of the peak work rate determined during pre-intervention incremental cycle testing. A precordial electrocardiogram lead approximating V5 was monitored continuously throughout the test. Another circulation time was determined near peak exercise, and the patient’s position was rechecked on the couch to ensure scanning at similar levels of the left ventricle as at rest. At 60% of peak work rate, the patients were re-injected with a similar bolus (30-40 cc) of non-ionic iodinated contrast material and rescanned to directly compare exercise results to the rest studies. The same protocol was used at post-

![Graphs showing changes in cardiac variables](image-url)

**Figure 2:** Changes induced by testosterone administration and/or resistance training in the four subject groups in cardiac variables at rest (bars represent mean and SE of change). P: placebo, no training; PR: placebo, resistance training; T: testosterone, no training; TR: testosterone, resistance training. Significant difference with respect to placebo-no training: *: p<0.05, **: p<0.005, ***: p<0.001. Significant difference from testosterone-resistance training: +: p<0.05.
intervention (week 12) and patients were exercised at the same work rate in both pre- and post-intervention exercise CT tests.

**Left and right ventricular ejection fraction assessment by CT:**

The CT images were evaluated by delineating the endocardium and epicardium at end-diastole and end-systole of each level of the heart by an investigator blinded to all demographics and treatment randomizations. The pre- and post-intervention measures were measured in random order, with the reader blinded to patient information and order of tests. On every 8 mm level (up to 12 per study), both right and left ventricular cavities were manually traced.

Each cross-sectional image of the left and right ventricle from base to apex was analyzed by a computerized wall motion analysis program [13]. Ejection fraction, end-systolic and end-diastolic volumes were calculated at each tomographic level. Using a computer summation program, global ejection fraction was obtained at rest and exercise as described previously [10,12,15]. Stroke volume was also calculated on every level, as well as the end-diastolic volume, end-systolic volume and myocardial mass. Total volumes and measures were a sum of all measures on every slice. Cardiac output was calculated from the total stroke volume times the heart rate. Myocardial mass was calculated for both the RV (not including the septum) and LV (including the septum and free wall).

**Statistical analysis**

All data are expressed as a mean ± standard deviation in text and tables and as ± standard error in figures. Differences among group baseline characteristics were determined using one-way analysis of variance (ANOVA). The changes between rest and exercise were analyzed using a paired t-test. Differences in responses to interventions among groups was determined with repeated measures ANOVA, using the Tukey post-hoc test to isolate differences between groups. Further, 2x2 factorial analysis, with testosterone administration and resistance training as the factors (with and without an interaction term), was utilized to determine whether these factors were significant predictors of changes in cardiac mass or contractility variables. Two-sided tests were used and significance was defined at the 0.05 level or below.

**Results**

Of the 52 patients randomized, 42 completed the protocol. Of the non-completers, one (in the testosterone + training group) was discontinued because of non-compliance with the protocol and 5 because of non-protocol related health problems (2 in the testosterone + training group and one each in the other 3 groups). Four additional patients did not undergo the follow up CT scan. Patients in the training groups completed at least 25 of the scheduled 30 sessions; those receiving testosterone averaged 27.5 sessions and those receiving placebo averaged 28.1 sessions. Patients tolerated the interventions well and no adverse events related to either training or to testosterone supplementation were recorded. Patient characteristics of the 42 subjects who completed the protocol are presented in Table 1; there were no significant differences among the four groups. On average, subjects had moderate to severe airflow obstruction on spirometry and...
circulating testosterone levels averaged 322ng/dL, substantially less than the 500-1000 ng/dl range generally seen in healthy young men.

No patient had any complications during EBCT exercise testing or contrast infusion. EBCT variables at rest and during exercise at study entry for the 42 participants are presented in Table 2. There were no significant differences in any of these variables among the four groups. RV ejection fraction was lower than normal in the entire cohort. Exercise was associated with a 72% increase in cardiac output (p<0.001). With exercise, end-diastolic volume of both chambers increased but ejection fraction did not change appreciably.

**Factorial analysis:** To determine whether testosterone and resistance training exerted independent and significant effects on cardiac mass or contractility variables, data from all subjects were entered into a linear regression model of the form:

\[ \Delta y = a_1 [\text{testosterone}] + a_2 [\text{resistance training}] + c \]

Where the independent variables assumed values of 1 or 0 depending on whether the individual received or did not receive the intervention and the independent variables are changes in measures of cardiac mass or contractility. The coefficients \(a_1\) and \(a_2\) are presented in Table 3. From this analysis, it is clear that receiving testosterone, but not resistance training, contributes significantly to increases in both right and left ventricular mass. Receiving resistance training, but not testosterone, contributes significantly to increases in left ventricular ejection fraction both at rest and during exercise. Neither intervention achieves a statistically significant effect on right ventricular ejection fraction. When an interaction term of the form \(a_3 [\text{testosterone}] [\text{resistance training}]\) was included in the model, \(a_3\) did not achieve statistical significance in any case, and ANOVA yielded similar neutral results.

**Table 3:** Regression coefficients for linear regression model to determine whether testosterone and/or resistance training were significant predictors of changes in cardiac mass or contractility variables. Primarily, LV and RV mass increased with testosterone, while ejection fractions increased with resistance training.

| Variable          | Regression Coefficient for Testosterone | P Value | Regression Coefficient for Resistance Training | P Value |
|-------------------|------------------------------------------|---------|-----------------------------------------------|---------|
| LV Mass (g)       | 6.09                                     | 0.022   | 2.22                                          | 0.39    |
| RV Mass (g)       | 5.68                                     | <0.001  | 2.66                                          | 0.014   |
| LV EF rest (%)    | 1.54                                     | 0.32    | 5.12                                          | 0.002   |
| LV EF exercise (%)| 2.82                                     | 0.065   | 4.44                                          | 0.005   |
| RV EF rest (%)    | 1.47                                     | 0.2     | 1.88                                          | 0.1     |
| RV EF exercise (%)| 1.85                                     | 0.13    | 1.82                                          | 0.13    |

LV, left ventricle; RV, right ventricle; EF, ejection fraction.

Intervention-associated changes in ejection fraction and end-diastolic volumes: Figure 2 and Figure 3 present changes associated with the interventions in cardiac variables at rest and during exercise, respectively. As compared with the placebo-no training group, both groups performing resistance training increased LVEF both at rest (Figure 2) and during exercise (Figure 3) with differences averaging from 5 to 7 percentage points. Changes in RVEF did not achieve statistical significance. As compared with the placebo-no training group, LV end-diastolic volume increased at rest in the testosterone plus resistance training group and in during exercise in both groups that received testosterone. As compared with the placebo-no training group, RV end-diastolic volume increased at rest in both groups that received testosterone and during exercise in all three other groups.

Intervention-associated changes in myocardial mass: As compared with the placebo-no training group, increase in left ventricular mass just failed to achieve statistical significance (p = 0.17 and 0.12 in the testosterone and testosterone plus resistance training groups, respectively) and right ventricular mass increased significantly in the two groups that received testosterone. These increases averaged 6-8 g (or roughly 6% and 10%), respectively. No significant change in the mass of either ventricle was seen in the group that received placebo and resistance training.

**Factorial analysis:** To determine whether testosterone and resistance training exerted independent and significant effects on cardiac mass and contractility variables, data from all subjects were entered into a linear regression model of the form:

\[ \Delta y = a_1 [\text{testosterone}] + a_2 [\text{resistance training}] + c \]

Where the independent variables assumed values of 1 or 0 depending on whether the individual received or did not receive the intervention and the independent variables are changes in measures of cardiac mass or contractility. The coefficients \(a_1\) and \(a_2\) are presented in Table 3. From this analysis, it is clear that receiving testosterone, but not resistance training, contributes significantly to increases in both right and left ventricular mass. Receiving resistance training, but not testosterone, contributes significantly to increases in left ventricular ejection fraction both at rest and during exercise. Neither intervention achieves a statistically significant effect on right ventricular ejection fraction. When an interaction term of the form \(a_3 [\text{testosterone}] [\text{resistance training}]\) was included in the model, \(a_3\) did not achieve statistical significance in any case, and ANOVA yielded similar neutral results.
Correlation analysis: Correlations among subjects of changes in cardiac mass and contractility with changes in body mass and leg muscle strength were determined. Changes in both left and right ventricular mass correlated with changes in whole body muscle mass (determined by DEXA scan) \(r=0.49, p<0.001\) and \(r=0.65, p<0.0001\), respectively (Figure 4). Changes in both rest and exercise left ventricular ejection fraction correlated with changes in leg muscle strength (assessed as 1 repetition maximum leg press) \(r=0.369, p=0.016\) and \(r=0.465, p=0.002\), respectively.

Discussion

This is one of the first studies demonstrating that testosterone, but not resistance training, increased LV and RV mass (by 4.9% and 8.3%, respectively). Resistance training, but not testosterone, was associated with increased LV ejection fraction at rest and during exercise (by 5.5% and 4.4%, respectively). In the entire study group, increases in both left and right ventricular mass were correlated with increases in lean body mass (assessed by DEXA) \(r=0.49\) and \(r=0.65\), respectively. Thus, in men with COPD, testosterone replacement and strength training are associated with distinct alterations in cardiac structure and function.

The cardiac effects of anabolic steroids have been demonstrated predominantly in body builders. Several studies demonstrated an increase in left ventricular end diastolic volume, left ventricular mass and/or worsening diastolic function [11-13], while other studies associated with distinct alterations in cardiac structure and function.

Correlations among subjects of changes in cardiac mass and contractility with changes in body mass and leg muscle strength were determined. Changes in both left and right ventricular mass correlated with changes in whole body muscle mass (determined by DEXA scan) \(r=0.49\) and \(r=0.65\), respectively (Figure 4). Changes in both rest and exercise left ventricular ejection fraction correlated with changes in leg muscle strength (assessed as 1 repetition maximum leg press) \(r=0.369\), \(p=0.016\) and \(r=0.465\), \(p=0.002\), respectively.

Discussion

This is one of the first studies demonstrating that testosterone, but not resistance training, increased LV and RV mass (by 4.9% and 8.3%, respectively). Resistance training, but not testosterone, was associated with increased LV ejection fraction at rest and during exercise (by 5.5% and 4.4%, respectively). In the entire study group, increases in both left and right ventricular mass were correlated with increases in lean body mass (assessed by DEXA) \(r=0.49\) and \(r=0.65\), respectively. Thus, in men with COPD, testosterone replacement and strength training are associated with distinct alterations in cardiac structure and function.

The cardiac effects of anabolic steroids have been demonstrated predominantly in body builders. Several studies demonstrated an increase in left ventricular end diastolic volume, left ventricular mass and/or worsening diastolic function [11-13], while other studies demonstrated no cardiovascular changes with anabolic steroid use [14-16], and/or worsening diastolic function [11-13], while other studies associated with distinct alterations in cardiac structure and function.

In the present study, factorial analysis demonstrated that resistance training was associated with increases in LV ejection fraction (by 5.1% at rest and 4.4% with exercise, Table 3). This magnitude of change is clinically significant, on par with improvements seen with afterload therapy in congestive heart failure [30]. This is not surprising, as exercise has demonstrated improved outcomes in other cohorts of patients [31]. In contrast, the trend for RV ejection fraction to increase with resistance training did not achieve statistical significance.

Testosterone therapy was associated with increases in both LV and RV mass in this study (averaging 6.1g and 5.7g, respectively, Table 3). These increases correspond to approximately a 4.9% increase in LV and 8.3% increase in RV mass. The findings of increasing LV and RV mass in this study is consistent with animal data. A study of castrated rats demonstrated that testosterone replacement led to an increase in LV mass, returning it back to pre-castration levels [32]. The increase in LV mass was in proportion to the change in body weight: the left ventricular weight/body weight ratio did not change [37]. A similar increase in LV mass was seen in human long distance runners and weight lifters, with LV mass increasing only to the extent that lean body mass is increased [33].

Previous studies have demonstrated benefit of testosterone replacement to increase skeletal muscle mass [34]. In our cohort, replacement doses of testosterone yielded increase lean body mass. In the group as a whole, increases in both LV and RV mass were correlated with the changes in lean body mass (Figure 4). The implications for a COPD population are significant, as lean body mass is often reduced and improvements in both lean body mass and cardiac mass may lead to better long term outcomes [3]. Though cardiac and whole body muscle mass are measured by very different methods, these results suggest that cardiac and skeletal muscle mass are controlled by similar factors. Several studies have demonstrated that the dose response to testosterone is related to lean body mass and obesity [42], supporting this observation.

Limitations

Cardiac CT exercising testing requires semisupine positioning. While semisupine bicycle ergometry results in lower peak heart rates and less change in ejection fractions in some radionuclide studies, the ability to detect CAD was no different using upright or supine exercise in these studies [35-37]. Patients with contrast allergies, renal insufficiency and those unable to exercise cannot undergo this CT evaluation. Radiation doses with the protocols utilized in this study are low, and the total radiation doses that patients received for these combined protocols were <6 mSev [38]. Due to the limited number of patients in the study, it is possible that some of the trends in individual groups may not have reached statistical significance. It is also possible that the treatment duration was not long enough to see all cardiovascular effects of these two interventions.

Overall, there remains a paucity of randomized clinical trials evaluating the cardiovascular effects of testosterone replacement, especially on cardiac outcomes. Whether testosterone replacement represents an adaptive response to low testosterone levels (positive response of increasing strength of skeletal and/or cardiac muscle) or just universally increases myocardial mass regardless of baseline levels (potentially negative effect) needs to be demonstrated in prospective trials. Multiple different mechanisms have been proposed, and large prospective human trials are warranted to evaluate whether these cardiac effects have a positive or negative effect on long term outcomes in males with lower hormone levels. In this study, resistance training improved ejection fraction, while testosterone increased lean body mass and LV mass.

Acknowledgments

We thank Hamid Bakhshesh, BSRT for his excellent technical assistance with this project. R. Casaburi occupies the Grancell/Burns Chair in the Rehabilitative Sciences.
References

1. Schols AM, Soeters PB, Mostert R, Pluyters RJ, Wouters EF (1995) Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 152: 1268-1274.

2. Ferreira IM, Verreschi IT, Nery LE, Goldstein RS, Zamel N, et al. (1998) The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 114: 19-28.

3. Yeh S-S, DeGuzman B, Kramer T (2002) Reversal of COPD-associated weight loss using the anabolic agent oxandrolone. Chest 122: 421-428.

4. Altamirano F, Gyarce C, Silva P, Toyos M, Wilson C, et al. (2009) Testosterone induces cardiomyocyte hypertrophy through mammalian target of rapamycin complex 1 pathway. J Endocrinol 202: 299-307.

5. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ (1998) The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 41: 1-15.

6. Ries AL, Carlin BW, Carrieri-Kohman V, Casaburi R, Celli BR, et al. (1997) Pulmonary rehabilitation: evidence based guidelines. Chest 112: 1336-1396.

7. Knudsen RJ, Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B (1983) Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 127: 725-734.

8. Casaburi (2004) Effects of Testosterone and Resistance Training in Men with Chronic Obstructive Pulmonary Disease. AJRCCM 170: 870-878.

9. Casaburi R, Bhasin S, Cosentino G, Porszasz J, Storer T, Anabolic Effects of Testosterone Replacement and Strength Training in Men with COPD. Submitted.

10. Chomka EV, Brundage BH (1999) Evaluation of left ventricular function by exercise bicycle ergometry ultrafast computed tomography. Brundage BH, ed. Comparative Cardiac Imaging. Rockville, MD: Aspen Publishing, 239 249.

11. De Piccoli B, Giada F, Benettin A, Sartori F, Piccolo E (1991) Anabolic steroid use in body builders: an echocardiographic study of left ventricular morphology and function. Int J Sports Med 12: 408-412.

12. Sachtleben TR, Berg KE, Elias BA, Cheatham JP, Felix GL, et al. (1993) The effects of anabolic steroids on myocardial structure and cardiovascular fitness. Med Sci Sports Exerc 25: 1240-1245.

13. Nieminen MS, Ramo MP, Viltasaalo M, Heikilla P, Karjalainen J, et al. (1996) Serious cardiovascular side effects of large doses of anabolic steroids in weightlifters. Eur Heart J 17: 1576-1583.

14. Palatini P, Giada F, Garavelli G, Sinisi F, Mario L, et al. (1996) Cardiovascular effects of anabolic steroids in weight-trained subjects. J Clin Endocrinol Metab 36: 1132-1140.

15. Salek RC, Rowland TW, Burke EJ (1985) Left ventricular size and function in bodybuilders using anabolic steroids. Med Sci Sports Exerc 17: 701-704.

16. Thompson PD, Sadianiantz A, Cullinane EM, Bodziony KS, Catlin DH, et al. (1992) Left ventricular function is not impaired in weightlifters who use anabolic steroids. J Am Coll Cardiol 19: 278-282.

17. Perry HM, Littlepage BNC (1992) Misusing anabolic drugs, take a drug history from well muscled patients. BMJ 350: 1241-1242.

18. Pugh PJ, English KM, Jones TH, Channer KS (2000) Testosterone: a natural tonic for the failing heart? QJM 93: 699-694.

19. Basaria S, Covello AD, Travison TG, Storer TW, Fairwell WR, et al. (2010) Adverse Events Associated with Testosterone Administration. N Engl J Med 363: 109-122.

20. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Bolano ER, et al. (2007) Events Associated with Testosterone Administration. N Engl J Med 363: 109-122.

21. Menke A, Guallar E, Rohrmann S, Nelson WG, Rifai N, et al. (2010) Sex steroid hormone concentrations and risk of death in US men. Am J Clin Nutr 91: 449-457.

22. Urtahausen A, Hopkins R, Kindermann W (1989) One- and two-dimensional echocardiography in bodybuilders using anabolic steroids. Eur J Appl Physiol 58: 633-640.

23. Brown KA, Okada RD, Boucher CA, Strauss W, Pohost GM (1984) Right ventricular ejection fraction response to exercise in patients with coronary artery disease: Influence of both right coronary artery disease and exercise-induced changes in right ventricular afterload. J Am Coll Cardiol 3: 895-901.

24. Rather SJ, Huang PJ, Friedman MI, Pierson RN (1989) Assessment of right ventricular anatomy and function by quantitative radionuclide ventriculography. J Am Coll Cardiol 13: 354-359.

25. Limacher MC, Quinones MA, Polliner LR, Nelson JG, Winters WL, et al. (1983) Detection of coronary artery disease with cine two-dimensional echocardiography: Description of a clinically applicable method and comparison with radionuclide ventriculography. Circulation 67: 1211-1218.

26. Marwick TH, Nemet JJ, Pasewark JF, Stewart WJ, Salcedo EE (1992) Accuracy and limitation of exercise echocardiography in a routine clinical setting. J Am Coll Cardiol 19: 74-81.

27. Reiter SJ, Rumberger JA, Feiring AJ, Stanford W, Marcus ML (1986) Precision of measurements of right and left ventricular volume by cine computed tomography. Circulation 74: 890-900.

28. Feiring AJ, Rumberger JA, Reiter SJ, Skorton DJ, Collins SM, et al. (1985) Determination of left ventricular mass in dogs with rapid-acquisition cardiac computed tomographic scanning. Circulation 72: 1355-1364.

29. Roig E, Georgiou D, Chomka EV, Wolfkli C, LoGalbo-Zak C, et al. (1991) Reproducibility of left ventricular myocardial volume and mass measurements by ultrafast computed tomography. J Am Coll Cardiol 18: 990-996.

30. The SOLVD investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293-302.

31. Krista AM, Edelstein SL, Hamman RF, Otto A, Bray GA, et al. (2006) Physical activity in individuals at risk for diabetes: Diabetes Prevention Program. Med Sci Sports Exerc 38: 826-832.

32. Cabral AM, Vasquez EC, Moyes MR, Antonio A (1988) Sex hormone modulation of ventricular hypertrophy in sinoaortic denervated rats. Hypertension 11: 193-197.

33. Longhurst JC, Kelly AR, Glyea WA, Mitchell JH (1980) Echocardiographic left ventricular masses in distance runners and weight lifters. J Appl Physiol 48: 154-162.

34. Bhasin S, TW Storer, N Berman, C Callegari, B Clevenger, et al. (1996) The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335: 1-7.

35. Oebbeken MD, Boucher CA, Okada RD, Bingham JB, Strauss HW (1988) Spectrum of global left ventricular responses to supine exercise. Am J Cardiol 51: 28-35.

36. Rodrigues EA, Maddahi J, Brown H, Pantaleo N, Freeman M, et al. (1989) Responses of left and right ventricular ejection fractions to aerobic and anaerobic phases of upright and supine exercise in normal subjects. Am Heart J 118: 319-324.

37. Manyari DE, Kostuk WJ (1983) Left and right ventricular function at rest and during bicycle exercise in the supine and sitting positions in normal subjects and patients with coronary artery disease. Am J Cardiol 51: 36 42.

38. Budoff MJ, Gillespie R, Georgiou D, Narahara KA, French WJ, et al. (1998) Comparison of Ultrafast Computed Tomography and Sestamibi in the Evaluation of Coronary Artery Disease. Am J Cardiol 81: 682-687.